653
mg/ml streptomycin, and 2 x 10-5 M 2-ME . The cells were transfected by electroporation (10) , distributed into 48-well plates, and selected by mycophenolic acid . Fluorochrome conjugates were purchased from Southern Biotechnology Associates, Inc., Birmingham, AL . Cytoplasmic (8) and surface stainings (11) were analyzed by fluorescence microscopy; surface stainings were analyzed, in addition, in the FACS (model 440; Becton Dickinson & Co., Mountain View, CA). K chains were detected with FITC-coupled goat anti-,u antiserum. The Ac38 V-region was identified by the antiidiotypic IgM/X, antibody B1-8 (12) , whose binding was detected by goat anti-X coupled to FITC . For biosynthetic labeling, 5 x 10' cells were incubated with 125 uCi [S5 S]methionine (1,000 Ci/mM; Amersham Corp ., Braunschweig, FRG) for 3 h in culture medium after a preincubation over a period of 1 .5 h in medium without methionine. Cell labeling, cell lysis, and precipitation of the Igs by Sepharose-bound antibodies were done according to reference 13 . Endoglycosidase H (Endo H) treatment was done after precipitation in 50 mM citrate buffer, pH 5.5, 0.02% SDS, 0 .1 M 2-ME, and 0.5 mM PMSF with 6 mU Endo H (Boehringer Mannheim, FRG) over 5 h. The proteins were separated by SDS-PAGE as described in reference 14 and two-dimensional gel analysis was performed according to reference 15 .
Results and Discussion
To analyze the expression of membrane-bound Igs in myeloma cells, the plasmid pSV1zmk38, encoding a um chain and a X chain, was stably introduced into the Ig-negative myeloma line X63-Ag8 .653 . Additionally, the um chain encoding construct pSVum38 was transfected into the X chain producing myeloma J558L. The transfected cells, X63umk38 and J558Lum38, were subsequently analyzed for surface IgM expression. As a control we also analyzed the um transfectant A20um38 of the B lymphoma line A20 that carries surface IgG2a/x. While A20um38 cells express high amounts of the transfected um chain on their surface (Fig . 1 A) , no IgM was detected on the surface of the X63umk38 (Fig. 1 C) and J558LAm38 transfectant (not shown) . Indeed, X63umk38 cells were as negative as the untransfected control lines A20 and X63-Ag8.653 (Fig .  1, B and D) .
On the other hand, intracellular Rm chain was identified in all transfected cell lines by cytoplasmic staining (data not shown) . Furthermore, , the antigen of Ac38 (5), was clearly bound as shown by intracellular staining of X63umk38, suggesting that functional antibodies are assembled inside the myeloma but obviously do not appear on the surface. Another J558L transfectant, containing a um vector encoding the B1-8 VH gene (4), gave identical staining results; i.e ., no surface but intracellular u chain was detected (data not shown) . This indicates that lack of surface expression of the membrane-bound antibody is independent of its V region .
The correct assembly of the antibody was also shown in a biochemical analysis of the intracellular antibodies in X63umk38 and A20um38 (Fig . 2) . The Igs were biosynthetically labeled, precipitated from cell lysate by Sepharose-coupled anti-X antibody, and subsequently analyzed on an acrylamide gel under reducing and nonreducing conditions . From both transfectants, H chains were coprecipitated with the L chains in roughly equal amounts (Fig . 2, lanes 2 and 3) . In lane 1 the precipitate from the myeloma line was size fractionated under nonreducing conditions ; apart from the free L chain, the HL dimer and also the complete antibody can be detected . These data prove that at least a significant fraction of the Am chains in the transfected myeloma cells is associated with L chain to full size antibodies . Evidence for biochemical identity of the Am chains derived from the lymphoma and myeloma cells was obtained by two-dimensional gel analysis ; the Am chains from the X63Amk38 (Fig . 3A) and the A20/.tm38 transfectant (Fig . 3B) were indistinguishable after IEF and subsequent size separation by SDS-PAGE . This result was expected, since in both transfectants Am transcripts of the correct size (2 .7 kb) could be detected with a probe specific for the sequence encoding the membrane portion of the Am chain (data not shown) . We conclude that the Am proteins in the myeloma and B lymphoma are identical, despite their different behavior in the cells.
Where in the myeloma cells is IgM arrested? Treatment of glycoproteins with Endo H gives information about their intracellular location . Only the rough endoplasmic reticulum-specific high-mannose glycosylation type is sensitive to the enzyme . Glycoproteins that reach the Golgi apparatus become complexly glycosylated and their sugar chains are no longer cleaved by Endo H.
The analysis of the Am chains from X63Amk38, J558LAm38, and A20Am38 is depicted in Fig. 4 . The undigested H chains of the myeloma cells (Fig . 4, lanes  1 and 3) show the molecular mass of the high-mannose glycosylated form (73 kD). Upon Endo H treatment all these chains are deglycosylated to a molecular mass of 62 kD (Fig . 4, lanes 2 and 4) . In contrast, in the B lymphoma, the Am protein is partly resistant to the enzyme . The undigestible material has a molecular mass of 78 kD, the size expected for Am chains carrying the complex sugar trees (Fig. 4, lane 6 [reference 17] ) . Thus, in the B lymphoma the membranebound antibodies reach the Golgi stack, in contrast to what is seen in the myeloma cells. A similar situation to the B lymphoma was observed in a Am/X transfected Abelson pre-B cell line (see reference 4) . The presence of only small amounts of complexly glycosylated um proteins in the B lymphoma may be due to different Am chain pool sizes in endoplasmic reticulum and Golgi complex .
Our data show that myeloma cells are unable to bring membrane-bound antibodies to the cell surface . However, these same cells can express on their surface the product of a transfected class I MHC gene (Weichel, W., personal communication), and thus do not seem to be generally deficient in transport and surface expression of membrane-bound proteins . The block of transport seems to be specific for the membrane-bound antibody molecule.
In principle, the selectivity of IgM transport can be due to two different kinds of control, depending on whether the proteins are targeted to the cell surface via a positively or negatively regulated mechanism . In the B lymphoma, surface expression of the antibody may occur only in concert with a second protein, whose expression is turned off in myeloma cells . This protein may play a role in the export ofthe antibody molecule and/or constitute with the antibody molecule part of an active antigen receptor complex on the surface of the B cell . Such a situation would be analogous to the antigen receptor on the T cell, where the T3 proteins are involved in function and transport of the a# heterodimer (18) . This is in line with the-finding that T cell receptor and surface Ig trigger a similar cellular response upon ligand crosslinking (19, 20) .
The alternative, namely that transport of membrane-bound Ig is negatively regulated in myeloma cells, implies a specific factor that hinders membranebound antibodies from being transported to the cell surface . Recent studies on protein transport, especially on secreted molecules, give increasing evidence that protein sorting occurs by selective retention (21) . Active retention of membranebound antibodies in myeloma cells would prohibit antigen triggering at this developmental stage . Summary Expression vectors coding for membrane-bound IgM antibodies were introduced into myeloma and B lymphoma cells . Only the lymphoma but not the myeloma cells were able to express the antibodies on the cell surface, although in both cases, complete antibodies were assembled intracellularly . In myeloma cells, the Ig molecules did not reach the Golgi compartment . Thus, the intracellular transport of membrane-bound antibodies is controlled in the B cell lineages in a developmentally ordered fashion .
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